Wuxi Biologics (Cayman) (2269) AI Stock Analysis

• Market Cap: $141.38B
• Dividend Yield: N/A
• Average Volume (3M): 41.59M
• Price to Earnings (P/E): 31.2
• Beta (1Y): 1.76
• Revenue Growth: 16.90%
• EPS Growth: 63.11%
• Country: HK
• Employees: 12,575
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.60
• Shares Outstanding: 4,064,897,700
• 10 Day Avg. Volume: 39,257,934
• 30 Day Avg. Volume: 41,590,806
• PEG Ratio: 0.00
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 3.60
• P/FCF Ratio: 52.28
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 5.17
• Enterprise Value/Gross Profit: 12.12
• Enterprise Value/Ebitda: 14.01
• 1Y Price Target: $39.09
• Price Target Upside: 11.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: HK$40.00 ▲(14.29% Upside)

Wuxi Biologics' strong financial performance is the primary driver of its overall score, supported by robust revenue growth and a stable capital structure. However, technical indicators suggest potential short-term weakness, and the high P/E ratio indicates possible overvaluation. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth highlights the company's ability to expand its market presence and increase its service offerings, ensuring long-term business sustainability.

Profitability

High and stable profit margins indicate effective cost management and strong pricing power, supporting sustained profitability and competitive advantage.

Balance Sheet Health

A low debt-to-equity ratio reflects conservative financial management, providing the company with greater flexibility to invest in growth opportunities without over-leveraging.

Negative Factors

Free Cash Flow Variability

Fluctuations in free cash flow can indicate challenges in capital allocation and may impact the company's ability to consistently fund new projects or return capital to shareholders.

Increasing Liabilities

Rising liabilities, if not managed carefully, could strain the company's financial resources and limit its ability to invest in future growth initiatives.

Cash Flow Fluctuations

Inconsistent cash flow can hinder the company's ability to plan long-term investments and may affect its financial stability during economic downturns.

Wuxi Biologics (Cayman) Business Overview & Revenue Model

Company Description

Wuxi Biologics (Cayman) Inc. is a leading global open-access biologics technology platform company headquartered in Wuxi, China. Specializing in the development and manufacturing of biologics, the company provides comprehensive services including cell line development, process development, and drug substance and product manufacturing. Wuxi Biologics serves a wide range of clients in the biopharmaceutical industry, from innovative biotech startups to established pharmaceutical companies, helping them bring monoclonal antibodies and other biologic products to market.

How the Company Makes Money

Wuxi Biologics generates revenue primarily through its contract development and manufacturing organization (CDMO) services. Key revenue streams include fees for its biologics manufacturing services, which encompass cell line development, upstream and downstream process development, and final product formulation and filling. The company also benefits from long-term partnerships and agreements with pharmaceutical companies, providing a steady flow of income through contract arrangements. Additionally, Wuxi Biologics earns revenue from its proprietary technologies and platforms that enhance the efficiency and yield of biologic production, further solidifying its position in the competitive biopharmaceutical market.

Wuxi Biologics (Cayman) Financial Statement Overview

Summary

Wuxi Biologics demonstrates strong financial health with robust revenue and profit growth, efficient cost management, and a stable capital structure. The low debt-to-equity ratio and positive cash flow trends further enhance its financial position, despite some fluctuations in free cash flow and a gradual increase in liabilities.

Income Statement

Wuxi Biologics has demonstrated strong revenue growth with a compound annual growth rate of over 20% from 2019 to 2024. The gross profit margin consistently exceeds 40%, indicating efficient cost management. The net profit margin has remained stable around 18% to 20%, showcasing solid profitability. EBIT and EBITDA margins are healthy, reflecting strong operational performance. Overall, the income statement highlights robust growth and profitability with minimal weaknesses.

Balance Sheet

The balance sheet of Wuxi Biologics is solid with a low debt-to-equity ratio of approximately 0.12, indicating conservative leverage. The equity ratio is strong, consistently above 70%, suggesting a stable capital structure. Return on equity is impressive, consistently above 8%, reflecting efficient use of shareholders' funds. However, the slight increase in total liabilities over time could be monitored for potential risk.

Cash Flow

Cash flow statements reveal positive trends with free cash flow turning positive in 2024 after previous years of negative figures. Operating cash flow has increased steadily, showing robust cash generation from operations. The free cash flow to net income ratio improved significantly, indicating enhanced cash efficiency. However, the variability in free cash flow over the years suggests some fluctuations in capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.05B	18.68B	17.03B	15.27B	10.29B	5.61B
Gross Profit	8.55B	7.65B	6.83B	6.72B	4.83B	2.53B
EBITDA	7.41B	6.43B	5.50B	6.22B	4.51B	2.31B
Net Income	4.20B	3.36B	3.40B	4.42B	3.39B	1.69B
Balance Sheet
Total Assets	60.44B	56.98B	56.58B	49.56B	44.03B	28.96B
Cash, Cash Equivalents and Short-Term Investments	12.54B	10.71B	11.24B	8.71B	11.13B	8.48B
Total Debt	5.11B	4.94B	4.56B	4.42B	4.30B	3.33B
Total Liabilities	11.37B	11.50B	12.56B	13.35B	11.33B	8.06B
Stockholders Equity	44.95B	41.82B	40.33B	35.05B	32.28B	20.56B
Cash Flow
Free Cash Flow	1.76B	1.29B	437.20M	-326.72M	-3.09B	-4.14B
Operating Cash Flow	5.72B	5.22B	4.67B	5.54B	3.43B	1.88B
Investing Cash Flow	-4.10B	-3.94B	-3.23B	-5.91B	-9.60B	-7.22B
Financing Cash Flow	-2.36B	-2.75B	1.96B	-2.59B	8.21B	6.57B

Wuxi Biologics (Cayman) Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 35.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2269, the sentiment is Negative. The current price of 35 is below the 20-day moving average (MA) of 36.20, below the 50-day MA of 37.22, and above the 200-day MA of 27.98, indicating a neutral trend. The MACD of -0.64 indicates Positive momentum. The RSI at 41.32 is Neutral, neither overbought nor oversold. The STOCH value of 19.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2269.

Wuxi Biologics (Cayman) Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2269	72 Outperform	$141.38B	31.20	9.79%	―	16.90%	63.11%
1530	68 Neutral	$72.78B	27.98	15.34%	0.83%	7.51%	44.09%
1801	55 Neutral	$148.82B	116.92	8.41%	―	52.78%	―
1177	54 Neutral	$124.66B	31.23	11.72%	1.29%	13.69%	50.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9926	43 Neutral	HK$102.43B	-109.23	-14.40%	―	33.46%	-7.60%
1877	43 Neutral	HK$39.44B	-25.46	-15.06%	―	39.02%	48.26%

Wuxi Biologics (Cayman) Corporate Events

Wuxi Biologics Proposes Revised Cap and Renewal of Service Agreement Amid Growing Demand

Wuxi Biologics announced a proposal to revise the annual cap for its 2023 Payload-Linkers Master Services Agreement due to increased demand and strong performance of the XDC Group. The company plans to renew the agreement for three more years, subject to shareholder approval, to accommodate the continued growth in demand for its ADC CRDMO services, reflecting its strategic positioning in the expanding biopharmaceutical market.

The most recent analyst rating on (HK:2269) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.

Wuxi Biologics Reports Strong Growth in H1 2025

Wuxi Biologics (Cayman) Inc. is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in biologics, providing comprehensive services from discovery to commercial manufacturing. The company is known for its integrated platform and strategic initiatives such as ‘Follow and Win the Molecule.’

WuXi Biologics to Present 2025 Interim Results in Upcoming Conference Calls

WuXi Biologics (Cayman) Inc. has announced it will hold conference calls on August 20, 2025, to present its 2025 interim financial results and business operations. This initiative aims to provide shareholders and potential investors with a comprehensive understanding of the company’s performance, although they are cautioned about the forward-looking nature of some statements in the presentation.

The most recent analyst rating on (HK:2269) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.

Wuxi Biologics Reports Strong Growth in H1 2025

Wuxi Biologics reported strong financial performance for the first half of 2025, with a 16.1% increase in revenue and a 54.8% rise in net profit compared to the previous year. The company secured 86 new integrated projects, bringing its total to 864, and demonstrated robust growth in both pre-clinical and commercial manufacturing projects, highlighting its sustainable development capabilities.

The most recent analyst rating on (HK:2269) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.